Updated:
Telegraph Hill Partners
Telegraph Hill Partners operates as a San Francisco-based private equity firm focused exclusively on the life science and healthcare sectors.
Telegraph Hill Partners
Telegraph Hill Partners operates as a San Francisco-based private equity firm focused exclusively on the life science and healthcare sectors. The firm targets commercial-stage companies with established revenues, a solid customer base, and management teams that have demonstrated sustainable growth. Its mandate spans growth equity, management buyouts, and founder liquidity transactions, with a stated preference for being the lead or sole institutional investor in any given round. The firm also executes corporate carve-outs, partnering with executives to acquire divisions from larger corporations and build them into independent entities. Investment activity concentrates on companies that provide foundational infrastructure for the healthcare industry. Target subsectors include discovery tools and automation, diagnostics, healthcare IT, and medical devices. A representative portfolio holding was Accumetrics, a developer of point-of-care diagnostic tests for cardiovascular and neurovascular disease, which was acquired by ITC Nexus in 2013. More recently, the firm led a Series B round into Kytopen, a biotechnology company advancing cell engineering platforms, as part of a broader commercialization push announced in April 2026 (per the firm, April 2026). The strategy demonstrates a consistent focus on enabling technologies rather than therapeutic assets or consumer-facing health services. Team composition draws on venture investors, life science operators, M&A professionals, and former entrepreneurs. While specific headcount and individual principals are not publicly itemized in available firm materials, the firm emphasizes a collaborative, generalist-partner model where deal teams work across all areas of the portfolio. Its San Francisco headquarters anchors investment operations, though the firm's website invites contact from companies nationwide. There is no public disclosure of dedicated philanthropic vehicles or external club affiliations linked to the manager. Telegraph Hill Partners' structural differentiator is its insistence on being the first institutional capital into bootstrapped life science companies, combined with a readiness to engineer corporate carve-outs — two deal types that require distinct underwriting skills most firms separate across early-stage venture and private equity teams. By housing both capabilities under one roof and refusing to diversify into other sectors, the firm creates a narrow but deep sourcing advantage in a technical market where generalist investors rarely compete for sub-scale infrastructure assets.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
San Francisco, CA, United States
Sector focus
Frequently asked questions
What investment stages does Telegraph Hill Partners target?
The firm focuses on commercial-stage companies with existing revenues and a demonstrated customer base, spanning growth equity and management buyouts. It is typically the first institutional investor in bootstrapped businesses and also structures founder liquidity transactions. Additionally, it executes corporate carve-outs, acquiring divisions from larger companies to operate them independently.
Which sectors does Telegraph Hill Partners explicitly avoid?
Telegraph Hill Partners concentrates exclusively on the life science and healthcare sectors, specifically discovery tools, automation, diagnostics, healthcare IT, and medical devices. The firm does not pursue therapeutic drug development, consumer health apps, or health services businesses outside its defined infrastructure focus. Its portfolio and public statements contain no evidence of activity outside these sub-sectors.
Does Telegraph Hill Partners participate in fund commitments or only direct deals?
All publicly available information describes direct investment activity — growth equity rounds, management buyouts, and founder liquidity deals — with no mention of fund-of-fund commitments or allocations to external managers. The firm's strategy page emphasizes being the lead or sole institutional investor, reinforcing a direct-only approach.
How does the firm source proprietary deal flow?
Sourcing relies on deep domain relationships within the life science tools, diagnostics, and device communities, often engaging companies that have bootstrapped to profitability without prior venture backing. The firm's public posture — inviting companies with revenues and solid customer bases to reach out directly — suggests a relationship-driven origination model rather than a broad auction-based process. Its ability to execute corporate carve-outs also provides access to deals that are structurally invisible to pure venture or pure buyout funds.
How is Telegraph Hill Partners structured — does it operate more like a venture firm or a traditional buyout shop?
The firm occupies a hybrid position: it writes equity checks into revenue-stage companies, resembling growth equity, but also pursues management buyouts and corporate carve-outs, which are hallmarks of traditional private equity. This dual capability, confined to a single sector vertical, differentiates it from both generalist venture firms and multi-sector mid-market buyout funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: